Overcoming resistance to exposure in panic disorder with agoraphobia

Acta Psychiatrica Scandinavica

Volumn 95, Issue 4, 1997, Pages 306-312

  Fava, G A ^a,b   Savron, G ^a   Zielezny, M ^c   Grandi, S ^a   Rafanelli, C ^a   Conti, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Agoraphobia; Behavioural therapy; Cognitive therapy; Imipramine; Panic disorder

Indexed keywords

IMIPRAMINE;

ADULT; AGORAPHOBIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; EXPOSURE; FEMALE; HUMAN; MALE; PANIC; PRIORITY JOURNAL;

EID: 0030891663     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1997.tb09636.x     Document Type: Article

References (30)

1. MARKS IM. Behavioural and drug treatments of phobic and obsessive-compulsive disorders. Psychother Psychosom 1986: 46: 35-44.
2. MARKS IM, SWINSON RP, BASOGLU M et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. Br J Psychiatry 1993: 162: 776-787.
3. FAVA GA, ZIELEZNY M, SAVRON G, GRANDI S. Long-term effects of behavioural treatment for panic disorder with agoraphobia. Br J Psychiatry 1995: 166: 87-92.
4. ROSENBAUM JF. Evaluation and management of the treatment-resistant anxiety disorder patient. Bul Menninger Clinic 1992: 56 (Suppl. 2A): A50-A60.
5. POLLACK MH, OTTO MW, KASPI SP, HAMMERNESS PG, ROSENBAUM JF. Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry 1994: 55: 200-205.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, revised 3rd edn. Washington, DC: American Psychiatric Association, 1987.
7. HOFFART A, DUE-HADSEN J, LANDE B, GUDE T, BILLE H, TORGERSEN S. Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. J Clin Psychiatry 1993: 54: 481-487.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994.
9. ENDICOTT J, SPITZER RL. A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 1978: 35: 837-844.
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd edn. Washington, DC: American Psychiatric Association, 1980.
11. FAVA GA, GRANDI S, CANESTRARI R, GRASSO P, PESARIN F. Mechanisms of change of panic attacks with exposure treatment of agoraphobia. J Affect Dis 1991: 22: 65-71.
12. BECK AT, EMERY G. Anxiety disorders and phobias. New York: Basic Books, 1985.
13. GOLDTHORPE JH, HOPE K. The social grading of occupations. Oxford: Oxford University Press, 1974.
14. SAVIOTTI FM, GRANDI S, SAVRON G et al. Characterological traits of recovered patients with panic disorder and agoraphobia. J Affect Dis 1991: 23: 113-117.
15. PAYKEL ES. The clinical interview for depression. J Affect Dis 1985: 9: 85-96.
16. MARKS IM, MATHEWS AM. Brief standard self-rating for phobic patients. Behav Res Therapy 1979: 17: 263-267.
17. FAVA GA, ZIELEZNY M, LURIA E, CANESTRARI R. Obsessive-compulsive symptoms in panic disorder with agoraphobia. Psychiatr Res 1988: 23: 57-63.
18. KELLNER R, UHLENHUTH EH, GLASS RM. Clinical evaluation of anti-anxiety agents: subject-own-control designs. In LIPTON MA et al., ed. Psychopharmacology. New York: Raven Press, 1978: 1392-1400.
19. GLASS RM, UHLENHUTH EH, MATUZAS W, MCCRACKEN S, GREENE S. Subject-own-control design in evaluating clinical antidepressant effects. J Affect Dis 1982: 4: 373-381.
20. FAVA GA. The concept of recovery in affective disorders. Psychother Psychosom 1996: 65: 2-13.
21. BASOGLU M, MARKS IM, SWINSON RP, NOSHIRVANI H, O'SULLIVAN G, KUCH K. Pre-treatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure. J Affect Dis 1994: 8-30: 123-132.
22. KEIJSERS GP, J HOOGDUIN CAL, SCHAAP CPDR. Prognostic factors in the behavioral treatment of panic disorder with and without agoraphobia. Behav Therapy 1994: 25: 689-708.
23. DREESSEN L, ARNTZ A, LUTTELS C, SALLAERTS S. Personality disorders do not influence the results of cognitive behavior therapies for anxiety disorders. Compr Psychiatry 1994: 35: 265-274.
24. EDELMAN RE, CHAMBLESS DL. Compliance during sessions and homework in exposure-based treatment of agoraphobia. Behav Res Therapy 1993: 8: 767-773.
25. ROSENBERG R, OTTOSSON JO, BECH P, MELLERGARD M. Alprazolam, imipramine and placebo treatment of panic disorder in Scandinavia. Acta Psychiatr Scand 1991: 83 (Suppl. 365): 7-52.
26. FAVA GA, GRANDI S, ZIELEZNY M, CANESTRARI R, MORPHY MA. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 1994: 151: 1295-1299.
27. FAVA GA, GRANDI S, ZIELEZNY M, RAFANELLI C, CANESTRARI R. Four-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1996: 153: 945-947.
28. EMMELKAMP PMG, MERSCH P. Cognition and exposure in vivo in the treatment of agoraphobia. Cogn Ther Res 1982: 6: 77-88.
29. DE BEURS E, VAN BALKOM AJLM, LANGE A, KOELE P, VAN DYCK R. Treatment of panic disorder with agoraphobia. Am J Psychiatry 1995: 152: 683-691.
30. SCHOLING A, EMMELKAMP PMG. Cognitive and behavioural treatments of fear of blushing, sweating or trembling. Behav Res Therapy 1993: 31: 155-170.